Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14829623 | 0.91 | HSD17B14 (0.45) | HPGDKCNQ3KCNQ2PIK3CAHDAC3 | |
| SCHEMBL14829626 | 0.90 | HPGD (0.46) | HPGDCDK6KCNQ3KCNQ2PIK3CD | |
| SCHEMBL14716084 | 0.89 | HDAC3 (0.45) | HPGDCDK6KCNQ3KCNQ2PIK3CD | |
| SCHEMBL14829518 | 0.88 | HDAC3 (0.52) | CDK6PIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL14829953 | 0.86 | HPGD (0.44) | HPGDCDK6KCNQ3KCNQ2PIK3CD | |
| SCHEMBL20246640 | 0.85 | HPGD (0.44) | HPGDCDK6KCNQ3KCNQ2PIK3CD | |
| SCHEMBL29624095 | 0.85 | HPGD (0.42) | HPGDCDK6KCNQ3KCNQ2PIK3CD | |
| SCHEMBL14829721 | 0.85 | HPGD (0.45) | HPGDCDK6KCNQ3KCNQ2PIK3CD | |
| SCHEMBL14829893 | 0.84 | HPGD (0.44) | HPGDCDK6KCNQ3KCNQ2PIK3CD | |
| SCHEMBL29623952 | 0.83 | CDK6 (0.41) | HPGDCDK6KCNQ3KCNQ2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249111-B2 | Substituted quinoxalines as B-RAF kinase inhibitors | NEUPHARMA, INC. (US) | 2016-02-02 | — | — | US | claimed |
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2014-11-20 | — | — | US | claimed |
| WO-2013049701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-04-04 | — | — | WO | claimed |
| US-20170050938-A1 | SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9249111-B2 | Substituted quinoxalines as B-RAF kinase inhibitors | NEUPHARMA, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2014-11-20 | — | — | US | disclosed |
| WO-2013049701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343068-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, RAF1 | HPGD 444/4885CDK6 98/4885KCNQ3 3488/4885 |
| US-20170050938-A1 | SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | HPGD 1545/4885CDK6 82/4885KCNQ3 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.